Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3021)	6/29/2020 2:52:59 PM
From: Felix B	Respond to of 3557

Thanks for sharing although I don't think it's known but there must be some implication on pricing due to BARDA funding

To: Miljenko Zuanic who wrote (3021)

6/29/2020 3:32:39 PM

From: Biotechwantabe

Read Replies (1) | Respond to of 3557

Regeneron Pharmaceuticals, Inc USAProduct Name: SarilumabDescription:
Kevzara (sarilumab) is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor

Unique Impact:
Conducted under the existing BARDA Regeneron OTA collaboration, a U.S. Phase 2/3 clinical trial will help determine if Kevzara can be used to reduce symptoms of inflammation in hospitalized people with critical or severe COVID-19

Status: Phase 2/3

Base Award Amount:	$16,368,388 (March 19, 2020)
Mod/Option 1 Amount:	$53,517,946 (June 17, 2020)